$VCNX
Vaccinex Inc

2023 Q3 Form 10-Q Financial Statement

#000095017023042073 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $20.00K $0.00
YoY Change -60.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.500M $2.027M
YoY Change 6.16% 30.1%
% of Gross Profit
Research & Development $4.355M $5.050M
YoY Change 27.0% 31.41%
% of Gross Profit
Depreciation & Amortization $31.00K $30.00K
YoY Change -53.73% -44.44%
% of Gross Profit
Operating Expenses $4.355M $5.050M
YoY Change 27.0% 31.41%
Operating Profit -$5.834M -$7.077M
YoY Change 21.74% 31.03%
Interest Expense $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $922.0K $17.00K
YoY Change 2611.76% -10.53%
Pretax Income -$4.912M -$7.060M
YoY Change 3.21% 31.15%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.912M -$7.060M
YoY Change 3.21% 31.15%
Net Earnings / Revenue -24560.0%
Basic Earnings Per Share -$1.09 -$0.12
Diluted Earnings Per Share -$1.09 -$0.12
COMMON SHARES
Basic Shares Outstanding 65.94M 54.86M
Diluted Shares Outstanding 4.507M 60.42M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $130.0K $1.908M
YoY Change -98.19% -83.26%
Cash & Equivalents $127.0K $1.908M
Short-Term Investments
Other Short-Term Assets $1.150M $760.0K
YoY Change 45.75% -11.73%
Inventory
Prepaid Expenses
Receivables $933.0K $11.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.206M $2.679M
YoY Change -72.51% -78.15%
LONG-TERM ASSETS
Property, Plant & Equipment $164.0K $177.0K
YoY Change -30.51% -30.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $352.0K $406.0K
YoY Change -40.03% 30.55%
TOTAL ASSETS
Total Short-Term Assets $2.206M $2.679M
Total Long-Term Assets $352.0K $406.0K
Total Assets $2.558M $3.085M
YoY Change -70.3% -75.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.225M $1.608M
YoY Change 755.26% 506.79%
Accrued Expenses $1.895M $1.533M
YoY Change 50.88% 40.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $75.00K $75.00K
YoY Change 1.35% 1.35%
Total Short-Term Liabilities $6.362M $3.383M
YoY Change 220.18% 126.89%
LONG-TERM LIABILITIES
Long-Term Debt $44.00K $63.00K
YoY Change -63.03% -54.35%
Other Long-Term Liabilities $20.00K $62.00K
YoY Change -89.36%
Total Long-Term Liabilities $44.00K $63.00K
YoY Change -63.03% -54.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.362M $3.383M
Total Long-Term Liabilities $44.00K $63.00K
Total Liabilities $6.427M $3.508M
YoY Change 180.17% 115.35%
SHAREHOLDERS EQUITY
Retained Earnings -$336.6M -$331.7M
YoY Change 6.99% 7.07%
Common Stock $332.8M $331.3M
YoY Change 3.68% 3.27%
Preferred Stock
YoY Change
Treasury Stock (at cost) $11.00K $11.00K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity -$3.870M -$423.0K
YoY Change
Total Liabilities & Shareholders Equity $2.558M $3.085M
YoY Change -70.3% -75.46%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$4.912M -$7.060M
YoY Change 3.21% 31.15%
Depreciation, Depletion And Amortization $31.00K $30.00K
YoY Change -53.73% -44.44%
Cash From Operating Activities -$3.090M -$5.507M
YoY Change -25.47% 3.26%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $0.00
YoY Change -140.82% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.00K $0.00
YoY Change -59.18% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.340M 4.092M
YoY Change -7152.63% -22833.33%
NET CHANGE
Cash From Operating Activities -3.090M -5.507M
Cash From Investing Activities -20.00K 0.000
Cash From Financing Activities 1.340M 4.092M
Net Change In Cash -1.770M -1.415M
YoY Change -58.0% -73.81%
FREE CASH FLOW
Cash From Operating Activities -$3.090M -$5.507M
Capital Expenditures $20.00K $0.00
Free Cash Flow -$3.110M -$5.507M
YoY Change -24.09% 4.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001205922
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38624
dei Entity Registrant Name
EntityRegistrantName
Vaccinex, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
16-1603202
dei Entity Address Address Line1
EntityAddressAddressLine1
1895 Mount Hope Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Rochester
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
14620
dei City Area Code
CityAreaCode
585
dei Local Phone Number
LocalPhoneNumber
271-2700
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
VCNX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65941086
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1908000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6391000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
175000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
760000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
912000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
2679000
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q4 us-gaap Assets Current
AssetsCurrent
7478000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
177000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
189000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
229000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
310000
CY2023Q2 us-gaap Assets
Assets
3085000
CY2022Q4 us-gaap Assets
Assets
7977000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1608000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1518000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1533000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
781000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
75000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
74000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
167000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
164000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3383000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2537000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
63000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
101000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
62000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
146000
CY2023Q2 us-gaap Liabilities
Liabilities
3508000
CY2022Q4 us-gaap Liabilities
Liabilities
2784000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65669245
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49881613
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65668393
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49880761
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
331279000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
324875000
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
852
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
852
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
11000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
11000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-331698000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-319676000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-423000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5193000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3085000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7977000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
550000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5050000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3843000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8862000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6809000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2027000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1558000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3751000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3186000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
7077000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
5401000
us-gaap Costs And Expenses
CostsAndExpenses
12613000
us-gaap Costs And Expenses
CostsAndExpenses
9995000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7077000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5401000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12063000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9995000
CY2023Q2 us-gaap Interest Expense
InterestExpense
0
CY2022Q2 us-gaap Interest Expense
InterestExpense
1000
us-gaap Interest Expense
InterestExpense
1000
us-gaap Interest Expense
InterestExpense
2000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7060000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5383000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12022000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9978000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7060000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5383000
us-gaap Net Income Loss
NetIncomeLoss
-12022000
us-gaap Net Income Loss
NetIncomeLoss
-9978000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7060000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5383000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12022000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9978000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60421128
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60421128
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42664051
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42664051
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55150945
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55150945
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40711167
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40711167
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7412000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13230000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
141000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4595000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
16188000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
138000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-5383000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10943000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5193000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2040000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
129000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4962000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2400000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4111000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
126000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-7060000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-423000
us-gaap Profit Loss
ProfitLoss
-12022000
us-gaap Profit Loss
ProfitLoss
-9978000
us-gaap Depreciation
Depreciation
61000
us-gaap Depreciation
Depreciation
95000
us-gaap Share Based Compensation
ShareBasedCompensation
255000
us-gaap Share Based Compensation
ShareBasedCompensation
279000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-164000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-152000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
45000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
90000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-795000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
753000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
115000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10547000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10329000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
49000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
52000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-49000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-52000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1150000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3519000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
38000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
37000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
5001000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
9710000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6113000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13192000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4483000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2811000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6391000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8589000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1908000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11400000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10500000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-331700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These condensed financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk, Other Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to a number of risks, including, but not limited to, the lack of available capital; the possible delisting of our common stock from Nasdaq, possible failure of preclinical testing or clinical trials; inability to obtain regulatory approval of product candidates; competitors developing new technological innovations; potential interruptions in the manufacturing and commercial supply operations; unsuccessful commercialization strategy and launch plans for its proprietary drug candidates; risks inherent in litigation, including purported class actions; market acceptance of the Company’s products; and protection of proprietary technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are deposited in interest-bearing money market accounts. Although the Company deposits its cash with multiple financial institutions, cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has historically raised capital in transactions with investors that include members of its board of directors and entities controlled by certain board members. As such, the Company's directors, directly and indirectly, control a significant ownership percentage of the Company. The Company can provide no assurances that future financing will be available in sufficient amounts or on terms acceptable to it or that its directors or entities controlled by certain board members will be willing or able to participate in future capital raises by the Company.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company depends on third-party manufacturers for the manufacture of drug substances and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company’s product candidates and adversely impact its results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
510206
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
592166
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
686959
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7494000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7445000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7317000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7256000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
177000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
189000
CY2023Q2 us-gaap Depreciation
Depreciation
30000
us-gaap Depreciation
Depreciation
61000
CY2022Q2 us-gaap Depreciation
Depreciation
54000
us-gaap Depreciation
Depreciation
95000
CY2023Q2 vcnx Accrued Clinical Trial Cost Current
AccruedClinicalTrialCostCurrent
1109000
CY2022Q4 vcnx Accrued Clinical Trial Cost Current
AccruedClinicalTrialCostCurrent
335000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
336000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
308000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
86000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
127000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1533000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
781000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
561198
CY2017Q4 vcnx Number Of Target Antigens Against Which Antibodies Are To Be Identified And Selected
NumberOfTargetAntigensAgainstWhichAntibodiesAreToBeIdentifiedAndSelected
2
CY2022Q4 vcnx Minimum Bid Price Requirement Per Share For Listing
MinimumBidPriceRequirementPerShareForListing
1.00
vcnx Stock Exchange Stock Trading Price Description
StockExchangeStockTradingPriceDescription
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company received a second 180-day compliance period, or until October 9, 2023, to regain compliance with the minimum bid price requirement. If our common stock maintains a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180-day compliance period, we will automatically regain compliance. In the event we do not regain compliance with the $1.00 bid price requirement by October 9, 2023,
CY2022Q4 vcnx Minimum Bid Price Requirement Threshold Consecutive Business Days To Regain Compliance
MinimumBidPriceRequirementThresholdConsecutiveBusinessDaysToRegainCompliance
P180D
CY2022Q4 vcnx Minimum Bid Price Requirement Per Share For Listing
MinimumBidPriceRequirementPerShareForListing
1.00
CY2022Q4 vcnx Minimum Consecutive Business Days For Which Closing Bid Price Must Be Maintained At Least One Point Zero Zero Per Share To Regain Compliance
MinimumConsecutiveBusinessDaysForWhichClosingBidPriceMustBeMaintainedAtLeastOnePointZeroZeroPerShareToRegainCompliance
P10D
CY2022Q4 vcnx Minimum Bid Price Requirement Per Share For Listing
MinimumBidPriceRequirementPerShareForListing
1.00
CY2023Q2 vcnx Minimum Stockholders Equity Required For Listing
MinimumStockholdersEquityRequiredForListing
2500000
CY2023Q2 vcnx Market Value Of Listed Securities
MarketValueOfListedSecurities
35000000
CY2023Q2 vcnx Net Income From Continuing Operations Related To Listing
NetIncomeFromContinuingOperationsRelatedToListing
500000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2400000
us-gaap Lessee Operating Lease Assumptions And Judgments Discount Rate Description
LesseeOperatingLeaseAssumptionsAndJudgmentsDiscountRateDescription
The leases do not provide an implicit rate so in determining the present value of lease payments, the Company its incremental borrowing rate for the applicable lease, which was 7.0%.
CY2023Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.070
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
240771
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11532
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
229239
us-gaap Operating Lease Payments
OperatingLeasePayments
90289
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
45144
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
43534
us-gaap Operating Lease Expense
OperatingLeaseExpense
90289
us-gaap Operating Lease Expense
OperatingLeaseExpense
87068
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3164524
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2166909
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1784093
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.98
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1375560
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3187
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
65820
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
14.90
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3090646
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1448331
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.82
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
126000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
138000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
255000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
279000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
vcnx Number Of Business Activity
NumberOfBusinessActivity
1
vcnx Number Of Segment Managers For Operations Or Operating Results
NumberOfSegmentManagersForOperationsOrOperatingResults
0
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
45144
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
43534
us-gaap Operating Lease Expense
OperatingLeaseExpense
90289
us-gaap Operating Lease Expense
OperatingLeaseExpense
87068

Files In Submission

Name View Source Status
0000950170-23-042073-index-headers.html Edgar Link pending
0000950170-23-042073-index.html Edgar Link pending
0000950170-23-042073.txt Edgar Link pending
0000950170-23-042073-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vcnx-20230630.htm Edgar Link pending
vcnx-20230630.xsd Edgar Link pending
vcnx-ex31_1.htm Edgar Link pending
vcnx-ex31_2.htm Edgar Link pending
vcnx-ex32_1.htm Edgar Link pending
vcnx-20230630_lab.xml Edgar Link unprocessable
vcnx-20230630_def.xml Edgar Link unprocessable
vcnx-20230630_cal.xml Edgar Link unprocessable
vcnx-20230630_pre.xml Edgar Link unprocessable
vcnx-20230630_htm.xml Edgar Link completed